Pharmacogenomic testing in oncology: a health system's approach to identify oncology provider perspectives.
Citation: Pharmacogenomics. 24(16):859-870, 2023 Nov.PMID: 37942634Institution: MedStar Institute for Innovation | MedStar Washington Hospital CenterDepartment: Associate Dean for Research Development | MedStar Health | National Center for Human Factors in Healthcare | Pharmacogenomics | Pharmacy ResidencyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Pharmacogenetics | *Pharmacogenomic Testing | Humans | Medical Oncology | Pharmacogenetics/ed [Education]Year: 2023ISSN:- 1462-2416
- Smith, D Max:
- https://orcid.org/0000-0003-3667-2936 Swain, Sandra M:
- https://orcid.org/0000-0002-1320-3830
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 37942634 | Available | 37942634 |
Aim: Identify oncology healthcare providers' attitudes toward barriers to and use cases for pharmacogenomic (PGx) testing and implications for prescribing anticancer and supportive care medications. Materials & methods: A questionnaire was designed and disseminated to 71 practicing oncology providers across the MedStar Health System. Results: 25 of 70 (36%) eligible oncology providers were included. 88% were aware of PGx testing and 72% believed PGx can improve care. Of providers who had ordered a medication with PGx implications in the past month, interest in PGx for anticancer (90-100%) and supportive care medications (>75%) was high. Providers with previous PGx education were more likely to have ordered a test (odds ratio: 7.9; 95% CI: 1.1-56; p = 0.0394). Conclusion: Oncology provider prescribing practices and interest in PGx suggest opportunities for implementation.
English